Huons of Huons Group is entering the vaccine market in partnership with Sanofi Korea (hereinafter referred to as Sanofi), the Korean affiliate of global biopharma company Sanofi.
Huons is pleased to announce a signed a distribution and co-promotion agreement with Sanofi for 5 vaccines on March 25 at Huons Headquarters.
Under this agreement, starting April 1, Huons will be responsible for the domestic distribution and co-promotion of five vaccine products, including ▲the influenza vaccines 'Vaxigrip (standard-dose)' and 'Efluelda (high-dose)', and in the field of adult vaccination, ▲the Tdap (Tetanus, Diphtheria, Pertussis) vaccine 'Adacel', ▲the hepatitis A vaccine 'Avaxim', and ▲the meningococcal vaccine 'MenQuadfi'.
Sanofi is an R&D-driven, AI-powered biopharma company, inventing medicines and vaccines that treat and protect millions of people around the world. By combining Sanofi's world's leading vaccines with Huons' specialized expertise in injectable sales and cold-chain logistics, both companies expect to create significant synergy in the domestic vaccine market.
To ensure systematic promotion of the new vaccine business, Huons has recently established a dedicated vaccine business unit. By leveraging experienced sales force and extensive customer networks, Huons plans to provide Korean healthcare professionals and patients with world-class access to vaccines.
In particular, Huons is committed to ensuring the stable delivery of temperature-sensitive vaccines to medical institutions nationwide by leveraging its cold chain expertise and logistics infrastructure built through distributing refrigerated injectables like 'Merit C Injection' and 'Hudaxin Injection'.
CEO of Huons Global Song Soo-young stated, "Our partnership with Sanofi—a trusted global leader in vaccines, recognized for its innovation—marks a key turning point in Huons' growth as a global public health partner. We are committed to setting a new standard in the domestic market by merging Sanofi's innovation with our localized sales expertise."
Furthermore, Huons aims to expand vaccine pipeline as a core growth engine through this strategic partnerships with a global biopharma company.